

Timothy D Gilligan

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8286442/timothy-d-gilligan-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

124
papers

2,675
citations

26
h-index

50
g-index

136
ext. papers

3,283
ext. citations

3.5
avg, IF

5.02
L-index

#	Paper	IF	Citations
124	Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3618-3632	2.2	227
123	American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3388-404	2.2	171
122	Testicular cancer. <i>Nature Reviews Disease Primers</i> , 2018 , 4, 29	51.1	164
121	Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1945-52	2.2	150
120	Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. <i>Clinical Cancer Research</i> , 2005 , 11, 4430-6	12.9	127
119	Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma 2018 , 6, 9		105
118	Chemotherapy for prostate cancer. <i>Urology</i> , 2002 , 60, 94-100; discussion 100	1.6	99
117	African-American men's perceptions about prostate cancer: implications for designing educational interventions. <i>Social Science and Medicine</i> , 2007 , 64, 2189-200	5.1	96
116	Racial differences in screening for prostate cancer in the elderly. <i>Archives of Internal Medicine</i> , 2004 , 164, 1858-64		78
115	Diagnosis and Treatment of Early Stage Testicular Cancer: AUA Guideline. <i>Journal of Urology</i> , 2019 , 202, 272-281	2.5	70
114	Social disparities and prostate cancer: mapping the gaps in our knowledge. <i>Cancer Causes and Control</i> , 2005 , 16, 45-53	2.8	64
113	Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 1529-1554	7.3	62
112	Ethical decision-making in critical care in Hong Kong. <i>Critical Care Medicine</i> , 1998 , 26, 447-51	1.4	62
111	A Phase II Study of Pazopanib in Patients with Localized Renal Cell Carcinoma to Optimize Preservation of Renal Parenchyma. <i>Journal of Urology</i> , 2015 , 194, 297-303	2.5	61
110	A church-based intervention to promote informed decision making for prostate cancer screening among African American men. <i>Journal of the National Medical Association</i> , 2010 , 102, 164-71	2.3	61
109	Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. <i>Cancer</i> , 2010 , 116, 5383-90	6.4	59
108	Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study. <i>Lancet Oncology</i> , 2019 , 20, 1386-1394 ⁵⁰	21.7	50

107	The REDE Model of Healthcare Communication: Optimizing Relationship as a Therapeutic Agent. <i>Journal of Patient Experience</i> , 2014 , 1, 8-13	1.3	43
106	Pathological evidence of necrosis in recurrent renal mass following treatment with sunitinib. <i>International Journal of Urology</i> , 2007 , 14, 1095-7; discussion 1097	2.3	42
105	Withdrawing life support: extubation and prolonged terminal weans are inappropriate. <i>Critical Care Medicine</i> , 1996 , 24, 352-3	1.4	38
104	Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer. <i>Annals of Oncology</i> , 2015 , 26, 833-838	10.3	36
103	Obstetric complications in pulmonary and critical care medicine. <i>Chest</i> , 1996 , 110, 791-809	5.3	36
102	Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab 2018 , 6, 107		36
101	Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 405-412	2.8	30
100	Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target. <i>Clinical Cancer Research</i> , 2019 , 25, 210-221	12.9	30
99	Absence of a correlation of androgen receptor gene CAG repeat length and prostate cancer risk in an African-American population. <i>Clinical Prostate Cancer</i> , 2004 , 3, 98-103		27
98	Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline Summary. <i>Journal of Oncology Practice</i> , 2018 , 14, 42-46	3.1	26
97	Defining the optimal treatment for clinical stage I nonseminomatous germ cell testicular cancer using decision analysis. <i>Journal of Clinical Oncology</i> , 2010 , 28, 119-25	2.2	25
96	Management of clinical stage I nonseminomatous germ cell testicular cancer. <i>Urologic Clinics of North America</i> , 2007 , 34, 137-48; abstract viii	2.9	25
95	Impact of race on survival in men with metastatic hormone-refractory prostate cancer. <i>Urology</i> , 2004 , 64, 212-7	1.6	25
94	The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2018 , 119, 160-163	8.7	25
93	Impact of Neoadjuvant Chemotherapy on Pathologic Response in Patients With Upper Tract Urothelial Carcinoma Undergoing Extirpative Surgery. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e1237-e1242	2.2	24
92	Rapid withdrawal of support. <i>Chest</i> , 1995 , 108, 1407-8	5.3	22
91	Management of localized seminoma, stage I-II: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009. <i>Urology</i> , 2011 , 78, S435-43	1.6	21
90	Intertubular growth in pure seminomas: associations with poor prognostic parameters. <i>Human Pathology</i> , 2005 , 36, 640-5	3.7	20

89	Whose death is it, anyway?. <i>Annals of Internal Medicine</i> , 1996 , 125, 137-41	8	20
88	Clinical Activity of Ipilimumab Plus Nivolumab in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020 , 18, 429-435	3.3	20
87	ASCO Clinical Practice Guideline on Uses of Serum Tumor Markers in Adult Males With Germ Cell Tumors. <i>Journal of Oncology Practice</i> , 2010 , 6, 199-202	3.1	18
86	Cessation of vascular endothelial growth factor-targeted therapy in patients with metastatic renal cell carcinoma: feasibility and clinical outcome. <i>Cancer</i> , 2012 , 118, 3277-82	6.4	17
85	Feasibility of Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients With Diminished Renal Function. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e879-e892	3.3	16
84	Clinical Effect of Dose Escalation After Disease Progression in Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, e275-e280	3.3	16
83	Neoplasms of the Testis 2012 , 837-870.e9		15
82	High-priority topics for cancer quality measure development: results of the 2012 American Society of Clinical Oncology Collaborative Cancer Measure Summit. <i>Journal of Oncology Practice</i> , 2014 , 10, e160-6 ^{3.1}		14
81	Testicular cancer survivorship. <i>Hematology/Oncology Clinics of North America</i> , 2011 , 25, 627-39, x	3.1	14
80	The atypical urothelial cancer patient: management of bladder cancers of non-transitional cell histology and cancers of the ureters and renal pelvis. <i>Seminars in Oncology</i> , 2007 , 34, 145-53	5.5	14
79	A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy 2019 , 7, 127		13
78	Effect of Switching Systemic Treatment After Stereotactic Radiosurgery for Oligoprogressive, Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, 413-419.e1	3.3	13
77	Management of low-stage nonseminomatous germ cell tumors of testis: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009. <i>Urology</i> , 2011 , 78, S444-55	1.6	13
76	The ASCO Quality Training Program: designing and implementing a medical specialty society-based quality improvement training program. <i>Journal of Oncology Practice</i> , 2014 , 10, 203-5	3.1	12
75	End-of-life discussions with patients. Timing and truth-telling. <i>Chest</i> , 1996 , 109, 11-2	5.3	12
74	Patient Characteristics, Treatment Patterns and Prognostic Factors in Squamous Cell Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e437-e442	3.3	12
73	Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma. <i>Targeted Oncology</i> , 2018 , 13, 599-609	5	12
72	Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials: Focus on Efficacy, Safety, and Response to Subsequent Therapies. <i>Targeted Oncology</i> , 2018 , 13, 353-361	5	11

71	Drug Holiday in Metastatic Renal-Cell Carcinoma Patients Treated With Vascular Endothelial Growth Factor Receptor Inhibitors. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e663-e667	3.3	11
70	Quality of life among testis cancer survivors. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 413-9	2.8	10
69	Rates of biochemical remission remain higher in black men compared to white men after radical prostatectomy despite similar trends in prostate specific antigen induced stage migration. <i>Journal of Urology</i> , 2007 , 178, 1271-6	2.5	10
68	Nivolumab treatment for patients with non-clear cell renal cell carcinoma: A multicenter retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4586-4586	2.2	10
67	Blood Myeloid-Derived Suppressor Cells Correlate with Neutrophil-to-Lymphocyte Ratio and Overall Survival in Metastatic Urothelial Carcinoma. <i>Targeted Oncology</i> , 2020 , 15, 211-220	5	9
66	Prognostic Factors and Risk Stratification in Invasive Upper Tract Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e751-e760	3.3	9
65	Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy. <i>Prostate</i> , 2018 , 78, 1035-1041	4.2	7
64	Decision Making in a Data-Poor Environment: Management of Brain Metastases From Testicular and Extragenadal Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2016 , 34, 303-6	2.2	6
63	Clinical outcome of patients (Pts) with metastatic renal cell carcinoma (mRCC) progressing on front-line immune-oncology based combination (IO-COMBO) regimens.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 613-613	2.2	6
62	Management of poor-prognosis testicular germ cell tumors. <i>Indian Journal of Urology</i> , 2010 , 26, 108-114	0.8	6
61	Patient-Clinician Communication Is a Joint Creation: Working Together Toward Well-Being. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018 , 38, 532-539	7.1	6
60	Challenges With the 8th Edition of the AJCC Cancer Staging Manual for Breast, Testicular, and Head and Neck Cancers. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 560-564	7.3	5
59	Myeloid-Derived Suppressor Cells in Nonmetastatic Urothelial Carcinoma of Bladder Is Associated With Pathologic Complete Response and Overall Survival. <i>Clinical Genitourinary Cancer</i> , 2020 , 18, 500-508	3.3	4
58	The association between facility case volume and overall survival in patients with metastatic renal cell carcinoma in the targeted therapy era. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 470.e19-470.e29	2.8	4
57	Is there such a thing as a cancer treatment that isn't worth its cost?. <i>Oncologist</i> , 2012 , 17, 3-4	5.7	4
56	Carboplatin for stage I seminoma. <i>Journal of Clinical Oncology</i> , 2006 , 24, 2971-2; author reply e32-3	2.2	4
55	Bicalutamide Monotherapy Compared with Castration in Patients with Nonmetastatic Locally Advanced Prostate Cancer: 6.3 Years of Follow-up. <i>Prostate Journal</i> , 2001 , 3, 42-43		4
54	Testis cancer: rare, but curable with prompt referral. <i>Cleveland Clinic Journal of Medicine</i> , 2007 , 74, 817-258		4

53	Evaluation of T cell infiltration in matched biopsy and nephrectomy samples in renal cell carcinoma. <i>Medicine (United States)</i> , 2018 , 97, e12344	1.8	4
52	Controversies in the management of early-stage germ cell tumors. <i>Current Oncology Reports</i> , 2009 , 11, 235-43	6.3	3
51	Outcomes of treatment cessation in select metastatic renal cell carcinoma (mRCC) patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4521-4521	2.2	3
50	Clinicopathologic factors, treatment patterns, and outcomes in micropapillary urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 439-439	2.2	3
49	ReCAP: Feasibility and Effectiveness of a Pilot Program to Facilitate Quality Improvement Learning in Oncology: Experience of the American Society of Clinical Oncology Quality Training Program. <i>Journal of Oncology Practice</i> , 2016 , 12, 177; e215-23	3.1	3
48	A 45-year-old with neuroendocrine carcinoma of the prostate. <i>Urology</i> , 2013 , 81, 714-6	1.6	2
47	Health and quality of life among survivors of testis cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 390-1	2.8	2
46	Identifying Prostate Surface Antigen Patterns of Change in Patients with Metastatic Hormone Sensitive Prostate Cancer Treated with Abiraterone and Prednisone. <i>Targeted Oncology</i> , 2020 , 15, 477-483	5.3	2
45	High-dose chemotherapy and autologous transplantation for testicular germ cell tumors. <i>Advances in Cell and Gene Therapy</i> , 2019 , 2, e47	1.2	1
44	Talking About Death. <i>Journal of Oncology Practice</i> , 2017 , 13, 672-674	3.1	1
43	If I paint a rosy picture, will you promise not to cry?. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3421-3	2.2	1
42	When do we stop talking about curative care?. <i>Journal of Palliative Medicine</i> , 2003 , 6, 657-60	2.2	1
41	Clinical activity of abiraterone acetate in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 99-99	2.2	1
40	ASCO Quality Training Program: A Five-Year Review. <i>JCO Oncology Practice</i> , 2020 , 16, e1243-e1248	2.3	1
39	Chemotherapy and Fertility. <i>Current Clinical Urology</i> , 2016 , 97-107		1
38	Ethical Issues of Care in the Cardiac Intensive Care Unit 2010 , 9-24		1
37	The Morbidity and Mortality Conference (MMC) in Oncology: A patient safety and root cause analysis (RCA)-driven approach at the Cleveland Clinic Taussig Cancer Institute (TCI).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 191-191	2.2	1
36	Adjuvant Chemotherapy in Bladder Cancer: A Good Concept But Where's the Proof? 2009 , 239-245		1

35	A Pathologic Fascination With Humanity. <i>Journal of Clinical Oncology</i> , 2018 , 36, 425-426	2.2	1
34	Real-world experience with atezolizumab (atezo) in advanced urothelial cancer (UC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, e16031-e16031	2.2	0
33	Outcomes and patterns of disease progression in metastatic renal cell carcinoma patients treated with nivolumab.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 654-654	2.2	0
32	Ethical Issues in the Cardiac Intensive Care Unit 2019 , 11-26.e3		0
31	Implications of the United States Preventive Services Task Force Recommendations on Prostate Cancer Stage Migration. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, e12-e16	3.3	0
30	Chemotherapy Is the Preferred Treatment for Seminomas Relapsing After First-line Chemotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 99, 511	4	
29	Personalizing Medicine. <i>Journal of Clinical Oncology</i> , 2019 , 37, 165-166	2.2	
28	What we really talk about when we talk about food. <i>Journal of Clinical Oncology</i> , 2015 , 33, 665-6	2.2	
27	Germ Cell Tumors 2014 , 645-650		
26	In reply. <i>Oncologist</i> , 2013 , 18, e2	5.7	
25	A case of spermatic cord teratoma in low-stage testicular cancer managed by surveillance. <i>Nature Reviews Urology</i> , 2008 , 5, 220-3		
24	Republication of SEMPET trial data?. <i>European Journal of Radiology</i> , 2006 , 58, 317; author reply 318	4.7	
23	Changing management of clinical low-stage testicular cancer. <i>Scientific World Journal, The</i> , 2005 , 5, 852-67z		
22	Retroperitoneal lymph node dissection versus chemotherapy for stage I testicular nonseminomas. <i>Annals of Oncology</i> , 2005 , 16, 172-3	10.3	
21	Overall Survival after Prostate-Specific-Antigen-Detected Recurrence Following Conformal Radiation Therapy.. <i>Prostate Journal</i> , 2001 , 3, 43-44		
20	Prospective Trial of the Herbal Supplement PC-SPEC in Patients with Progressive Prostate Cancer.. <i>Prostate Journal</i> , 2001 , 3, 44-45		
19	Biochemical Outcome Following External Beam Radiation Therapy With or Without Androgen Suppression Therapy for Clinically Localized Prostate Cancer.. <i>Prostate Journal</i> , 2001 , 3, 45-46		
18	Testis Cancer 2006 , 851-880		

- 17 Atezolizumab (atezo) and subsequent therapies in patients (Pts) with metastatic urothelial carcinoma (mUC) outside clinical trials.. *Journal of Clinical Oncology*, **2018**, 36, 432-432 2.2
- 16 Impact of neoadjuvant chemotherapy on pathologic outcomes in patients with upper tract urothelial carcinoma undergoing extirpative surgery.. *Journal of Clinical Oncology*, **2018**, 36, 457-457 2.2
- 15 The association between HSD3B1 genotype and steroid metabolism in normal and prostate cancer (PCa) tissue.. *Journal of Clinical Oncology*, **2018**, 36, TPS155-TPS155 2.2
- 14 Response to platinum-based therapy (PBT) and immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (mUC) patients (pts) with genomic alterations (GA) in homologous recombination repair (HRR) genes.. *Journal of Clinical Oncology*, **2018**, 36, 447-447 2.2
- 13 Treatment patterns for metastatic hormone-sensitive prostate cancer (mHSPC) progressing after up-front docetaxel in combination with androgen deprivation therapy (D-ADT).. *Journal of Clinical Oncology*, **2018**, 36, 305-305 2.2
- 12 Immunological correlates of response to immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (mUC) patients (pts).. *Journal of Clinical Oncology*, **2018**, 36, 454-454 2.2
- 11 Cisplatin-based neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC) in patients (pts) with impaired renal function.. *Journal of Clinical Oncology*, **2018**, 36, 446-446 2.2
- 10 The impact of switching systemic treatment after radiosurgery (SBRT) for oligo-progressive, metastatic renal cell carcinoma (mRCC).. *Journal of Clinical Oncology*, **2018**, 36, 599-599 2.2
- 9 Serial changes in PD1/PDL1 expression in metastatic urothelial carcinoma (mUC) patients (pts) treated with immune checkpoint blockade (CPB).. *Journal of Clinical Oncology*, **2018**, 36, 109-109 2.2
- 8 Implications of the United States Preventive Services Task Force (USPSTF) recommendations on prostate cancer (PCa) stage migration.. *Journal of Clinical Oncology*, **2019**, 37, 5071-5071 2.2
- 7 A phase II study of pazopanib (P) in patients (Pts) with localized renal cell carcinoma (RCC) to enable partial nephrectomy (PN).. *Journal of Clinical Oncology*, **2014**, 32, 4522-4522 2.2
- 6 Clinical Implications of the Different Histologic Subtypes of Testicular Tumors **2015**, 483-489
- 5 Clinical effect of TKI dose-escalation after disease progression in patients with metastatic renal cell carcinoma.. *Journal of Clinical Oncology*, **2015**, 33, 4562-4562 2.2
- 4 T cell infiltration (TCI) in matched renal biopsy (bx) and nephrectomy (nx) samples in renal cell carcinoma (RCC).. *Journal of Clinical Oncology*, **2017**, 35, 4587-4587 2.2
- 3 To better manage cancer symptoms. *Cleveland Clinic Journal of Medicine*, **2011**, 78, 24 2.8
- 2 Immune cell repertoire in patients with indolent metastatic renal cell carcinoma.. *Journal of Clinical Oncology*, **2013**, 31, 429-429 2.2
- 1 Implementing a comprehensive physician-communication-skills improvement initiative: The Cleveland Clinic experience.. *Journal of Clinical Oncology*, **2013**, 31, 186-186 2.2